Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CTP6 | ISIN: US00509G2093 | Ticker-Symbol:
NASDAQ
02.10.25 | 22:00
1,770 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACUMEN PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACUMEN PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ACUMEN PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.Acumen Pharmaceuticals stellt auf Citi-Konferenz neue Alzheimer-Strategie vor6
14.08.Acumen Pharmaceuticals: BTIG bestätigt Kaufempfehlung für vielversprechenden Alzheimer-Wirkstoff5
12.08.Acumen Pharmaceuticals, Inc. - 10-Q, Quarterly Report4
12.08.Acumen Pharmaceuticals, Inc. - 8-K, Current Report1
12.08.Acumen Pharmaceuticals GAAP EPS of -$0.68 misses by $0.161
12.08.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights126Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted...
► Artikel lesen
11.08.Acumen Pharmaceuticals' Earnings: A Preview1
28.07.Acumen Pharma Cuts Alzheimer's Trial Costs 40% With Blood Test1
ACUMEN PHARMACEUTICALS Aktie jetzt für 0€ handeln
28.07.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association ...2
15.07.Acumen Pharmaceuticals, Inc. - 8-K, Current Report3
15.07.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease297Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical...
► Artikel lesen
10.07.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International ...3
17.06.Citi initiates Acumen Pharmaceuticals stock with buy rating12
05.06.Acumen Pharmaceuticals, Inc. - 8-K, Current Report2
13.05.Acumen Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
13.05.Acumen Pharmaceuticals, Inc. - 8-K, Current Report-
13.05.Acumen Pharmaceuticals GAAP EPS of -$0.48 beats by $0.064
12.05.A Preview Of Acumen Pharmaceuticals' Earnings2
06.05.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 20251
26.03.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease167NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1